Clinical Trial Update: Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of denileukin diftitox in metastatic melanoma or metastatic kidney cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Kidney Cancer, Melanoma (Skin) | Phase 2 | Status: COMPLETED